NCT02760914|Active Not Recruiting
Adipose Tissue and Inflammation in Coronary Heart Disease
ATICH
Inflammatory Activity in Various Compartments of Adipose Tissue in Patients With Coronary Heart Disease
Loading search results
ATICH
Inflammatory Activity in Various Compartments of Adipose Tissue in Patients With Coronary Heart Disease
Sponsor study identifier
observational
50
1 country
1
Study Start
June 2016
Actual (reported)Primary Completion
December 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The aims of the present project are to study possible differences in inflammatory gene expression and protein secretion in various compartments of adipose tissue being exposed during open cardiac surgery in patients with coronary heart disease undergoing coronary artery bypass surgery.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 2, 2016
Actual (reported)May 4, 2016
Actual (reported)June 2016
Actual (reported)December 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Inflammasome-related proteins
Inflammasome-related proteins (IL-18, IL-1b, NLRP3, Caspase, TLR4, IL-6, IL-6R, gp130), markers of remodeling (i.e. MMP-9, TIMP-1, PAI-1, Galectin, EMMPRIN), adipokines (i.e adiponectin, visfatin), other relevant pro-and anti-inflammatory cytokines (like TNF-alpha, IL-8, IL-12, IFN-gamma, MCP-1, IL-4, IL-10, TGF beta.) Relevant laboratory methods; qPCR (mRNA - all compartments + PAXGenetubes (leukocytes); Immunohistochemically; Circulating (where possible) (ELISAs and/or Multiplex). Results will be recorded in a database for further statistical analyses.
At inclusion
Patients with coronary heart disease undergoing planned coronary artery bypass surgery
Patients with coronary heart disease undergoing planned coronary artery bypass surgery.
Svein Solheim
Oslo, 0407, Norway
Opstad TB, Papotti B, Akra S, Hansen CH, Braathen B, Tonnessen T, Solheim S, Seljeflot I. Sirtuin1, not NAMPT, possesses anti-inflammatory effects in epicardial, pericardial and subcutaneous adipose tissue in patients with CHD. J Transl Med. 2023 Sep 21;21(1):644. doi: 10.1186/s12967-023-04518-4.
adipose tissue, whole blood
Ingebjørg Seljeflot, Professor
Oslo University Hospital, Ullevål, Oslo, Norway
First Submitted
May 2, 2016
First Posted
May 4, 2016
Study Start
June 2016
Actual (reported)Primary Completion
December 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Risk Reduction in Coronary Heart Disease
Contact the study team to confirm eligibility.
Study Completion
December 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
February 26, 2021
Record last verified: 2021-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: